Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc. is a biotechnology company focused on developing therapies for fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and other conditions involving abnormal tissue scarring. The company’s research programs are centered on small-molecule treatments intended to address the underlying processes that contribute to fibrosis.

Its lead investigational product is F351, also known as hydronidone, an orally administered anti-fibrotic compound designed to inhibit pathways involved in collagen production and tissue scarring. F351 has been studied in clinical programs for IPF and other fibrotic disorders, although its development status and regulatory availability may vary by geography.

Gyre Therapeutics was formed through the transformation of Catalyst Biosciences following a 2023 transaction involving Gyre Pharmaceuticals and companies affiliated with GNI Group. Through its relationship with Gyre Pharmaceuticals, the company maintains a development and commercial presence in China while pursuing broader international opportunities, including clinical development in the United States.

Key Stats

• Today's Range: $6.81 to $7.44
• 50-Day Range: $5.64 to $7.55
• 52-Week Range: $5.44 to $9.42
• Volume: 327,687 shs
• Average Volume: 156,271 shs
• Market Capitalization: $817.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Reduce

Gyre Therapeutics Stock Analysis - MarketRank™

Gyre Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 699th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Gyre Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Gyre Therapeutics has a consensus price target of $16.00, representing about 118.3% upside from its current price of $7.33.

Amount of Analyst Coverage

Gyre Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gyre Therapeutics is -34.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gyre Therapeutics is -34.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Gyre Therapeutics has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.71% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 19.22, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently increased by 1.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gyre Therapeutics does not currently pay a dividend.

Dividend Growth

Gyre Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.42

News Sentiment

Gyre Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Gyre Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.50% of the stock of Gyre Therapeutics is held by insiders.

Percentage Held by Institutions

23.99% of the stock of Gyre Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CIK: 1124105
• Web: www.gyretx.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 618
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Gyre Therapeutics: $16.00
• High Price Target: $16.00
• Low Price Target: $16.00
• Potential Upside/Downside: +118.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.03 million
• Net Margins: -15.47%
• Pretax Margin: -10.30%
• Return on Equity: -6.57%
• Return on Assets: -5.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.26
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $116.59 million
• Price / Sales: 7.01
• Cash Flow: $0.22 per share
• Price / Cash Flow: 33.71
• Book Value: $1.48 per share
• Price / Book: 4.95

Miscellaneous

• Outstanding Shares: 111,510,000
• Free Float: 100,917,000
• Market Cap: $817.37 million
• Optionable: No Data
• Beta: 1.92